Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 2/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.47 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.47 |
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.44 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.56 |
| ▸ | POLB | P06746 | 8/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.56 |
| ▸ | FEN1 | P39748 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932749 | 0.98 | — | — | |
| SCHEMBL1651850 | 0.80 | CES2 (0.70) | ALDH1A1POLBHSD17B10HPGDRECQL | |
| SCHEMBL6320074 | 0.80 | ERCC5 (0.74) | ALDH1A1POLBHSD17B10HPGDRECQL | |
| Hydrochloric Acid SCHEMBL28153000 | 0.79 | ALDH1A1 (0.56) | ALDH1A1POLBHSD17B10HPGDRECQL | |
| SCHEMBL6196587 | 0.78 | — | — | |
| SCHEMBL574955 | 0.78 | — | — | |
| SCHEMBL5369014 | 0.78 | — | — | |
| SCHEMBL7070914 | 0.78 | ERCC5 (0.71) | ALDH1A1POLBHSD17B10HPGDRECQL | |
| SCHEMBL51450 | 0.78 | — | — | |
| SCHEMBL183688 | 0.78 | ERCC5 (0.65) | ALDH1A1POLBHSD17B10HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819366-B | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-111606888-B | Pyrrole derivative and preparation method and application thereof | 中国药科大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-115819366-A | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2023-03-21 | — | — | CN | disclosed |
| EP-2875005-B1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS INC (CN) | 2020-11-11 | — | — | EP | disclosed |
| CN-111606888-A | Pyrrole derivative and preparation method and application thereof | 中国药科大学 | 2020-09-01 | — | — | CN | disclosed |
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-06-09 | — | — | US | disclosed |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2015-07-09 | — | — | US | disclosed |
| EP-2875005-A1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | Impact Therapeutics, Inc. (CN) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014012511-A1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | WO | disclosed |
| EP-1756089-B1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-22 | — | — | EP | disclosed |
| EP-0399645-B1 | Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1994-11-09 | — | — | EP | disclosed |
| EP-0435840-A2 | Process for the preparation of 2-(2-furyl) ethanol amine | MONSANTO COMPANY (US) | 1991-07-03 | — | — | EP | disclosed |
| EP-0399645-A2 | Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1990-11-28 | — | — | EP | disclosed |
| CN-1046332-A | New compound | BEECHAM GROUP PLC (GB) | 1990-10-24 | — | — | CN | disclosed |
| US-4962212-A | Process for the preparation of 2-(2-furyl)ethanol amine | MONSANTO COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
| EP-0120270-B1 | FURYLOXAZOLYLACETIC ACID DERIVATIVE, PROCESSES FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION | Tanabe Seiyaku Co., Ltd. (JP) | 1989-09-27 | — | — | EP | disclosed |
| US-4642313-A | ANTILIPEMIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1987-02-10 | — | — | US | disclosed |
| EP-0087782-B1 | FURYLOXAZOLYLACETIC ACID DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Tanabe Seiyaku Co., Ltd. (JP) | 1986-05-21 | — | — | EP | disclosed |
| EP-0120270-A2 | Furyloxazolylacetic acid derivative, processes for preparing same and pharmaceutical composition | Tanabe Seiyaku Co., Ltd. (JP) | 1984-10-03 | — | — | EP | disclosed |
| EP-0087782-A1 | Furyloxazolylacetic acid derivatives, process for preparing same and pharmaceutical compositions containing same | Tanabe Seiyaku Co., Ltd. (JP) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | SHH, GLI1, SMO | ESR2 790/4885GAA 4122/4885ESR1 1962/4885 |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | SHH, GLI1, SMO | ESR2 790/4885GAA 4122/4885ESR1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.